(Q34112243)

English

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Primary mutations selected in vitro with raltegravir confer large fold changes in susceptibility to first-generation integrase inhibitors, but minor fold changes to inhibitors with second-generation resistance profiles (English)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

1 reference

based on heuristic

inferred from title

object named as

Ann Vos

2

0 references

Dominique Schols

object named as

Dominique Schols

6

0 references

author name string

Olivia Goethals

1

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Marcia Van Ginderen

3

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Peggy Geluykens

4

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Veerle Smits

5

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Kurt Hertogs

7

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Reginald Clayton

8

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

language of work or name

0 references

publication date

24 April 2010

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

number of pages

9

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

402

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

2

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

338-346

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

Raltegravir (MK-0518): a novel integrase inhibitor for the treatment of HIV infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Molecular mechanisms in retrovirus DNA integration

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Raltegravir: a new antiretroviral class for salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Modeling, analysis, and validation of a novel HIV integrase structure provide insights into the binding modes of potent integrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

HIV Drug Resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Antiviral activity, pharmacokinetics, and dose response of the HIV-1 integrase inhibitor GS-9137 (JTK-303) in treatment-naive and treatment-experienced patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

HIV-1 DNA integration: Mechanism of viral DNA cleavage and DNA strand transfer

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

HIV integrase structure and function.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Development of resistance against diketo derivatives of human immunodeficiency virus type 1 by progressive accumulation of integrase mutations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Safety and efficacy of the HIV-1 integrase inhibitor raltegravir (MK-0518) in treatment-experienced patients with multidrug-resistant virus: a phase II randomised controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870,810 and cross-resistance to the clinical trial drug GS-9137.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Nucleosides. V. The Monomesylates of 1-(2'-Deoxy-β-D-lyxofuranosyl)thymine1,2

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: the Swiss HIV Cohort Study

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Antiretroviral activity, pharmacokinetics, and tolerability of MK-0518, a novel inhibitor of HIV-1 integrase, dosed as monotherapy for 10 days in treatment-naive HIV-1-infected individuals

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Effect of HIV integrase inhibitors on the RAG1/2 recombinase

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Secondary mutations in viruses resistant to HIV-1 integrase inhibitors that restore viral infectivity and replication kinetics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Integrase inhibitors to treat HIV/AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Natural selection results in conservation of HIV-1 integrase activity despite sequence variability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

HIV chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Antiviral drug resistance

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Novel HIV-1 integrase inhibitors derived from quinolone antibiotics

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Raltegravir with optimized background therapy for resistant HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Selection conditions affect the evolution of specific mutations in the reverse transcriptase gene associated with resistance to DMP 266.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Novel inhibitors of HIV-1 integration.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Requirement for integrase during reverse transcription of human immunodeficiency virus type 1 and the effect of cysteine mutations of integrase on its interactions with reverse transcriptase.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

Human immunodeficiency virus type 1 integrase: effect on viral replication of mutations at highly conserved residues.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2010.03.034

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VIROL.2010.03.034

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

release_sdvd5nfcwjhfpdce5reo7kmkx4

1 reference

https://api.fatcat.wiki/v0/release/sdvd5nfcwjhfpdce5reo7kmkx4

24 November 2022

based on heuristic

mapped directly with Wikidata item

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

31 July 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q34112243&oldid=1960466274"